Randomized controlled clinical trial on the effect of Hyperbaric Oxygen Therapy (HBO) in non intubated COVID-19 hospitalized patients

Hospital Risoleta Tolentino Neves0 个研究点开始时间: 2021年8月16日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Patients over 18 years of age; diagnosis confirmed by laboratory tests or computed tomography (CT) of the chest compatible with COVID-19; oxygen saturation below 93% in ambient air; respiratory frequency greater than or equal to 24 resp / min; without a significant commitment from other bodies or systems.

•Hemodynamic instability, defined by mean arterial pressure less than 60 mmHg; respiratory failure requiring intubation; blood levels of TGO/TGP greater than 5 times the upper limit of normal; several chronic kidney diseases in stage 4; kidney disease requiring dialysis, that is, with eGFR (Estimated Glomerular Filtration Rate) less than 30 mL/min; transition planned to another hospital, other than a place of study, within 72 hours; infection with the human immunodeficiency virus under highly active antiretroviral therapy (HAART); history of severe depression or attempted suicide or current suicidal ideation; contraindications related to the administration of hyperbaric oxygen: pregnancy; breast-feeding; untreated pneumothorax; use of adriblastine, cisplatin, doxorubicin and mafenide; topical use of iodine and / or petrolatum; advanced emphysema with CO2 retention; claustrophobia; other conditions identified by the hyperbarist team.

发起方